Abnormalities of the karyotype in chronic myeloproliferative neoplasia
А.М. SAVRILOVA, А.R. AKHMADEEV, A.S. KHAYRULLOV, S.N.TEREKHOVA
Republican Clinical Hospital of the MH of RT, 138 Orenburgskiy Trakt, Kazan, Russian Federation, 420064
Savrilova A.M. — haematologist of consultative polyclinic, tel. +7-905-312-63-09, e-mail: alsu-mindubaeva@yandex.ru
Akhmadeev A.R. — Head of Hematology Department, tel. +7-927-240-55-90, e-mail: ahmadeev_ar@mail.ru
Khayrullov A.S. — Cand. Med. Sc., deputy chief physician of polyclinic section work, tel. (843) 231-20-45, e-mail: Ayrat.Hayrullov@tatar.ru
Terekhova S.N. — Cand. Med. Sc., Head of the Department of gravitational blood surgery, tel. +7-927-401-16-24, e-mail: sntdoc@rambler.ru
Frequency of occurrence of the JAK2V617F mutation for patients with different variants of сhronic myeloproliferative disorders (CMPD) is observed. Assessment in order to get differentional diagnostics of CMPD with nonproliferative diseases of the blood was evaluated in 79 cases of 128 (that is 61.7%). The cytogenetical research showed that 2 patients of 20 (10%) have clonal chromosome aberrations with poor prognosis.
Key words: chronic myeloproliferative disorders, JAK2V617F mutation, chromosome aberrations.
REFERENCES
- Abdulkadyrov K.M. Spravochnik «Klinicheskaya gematologiya» [Guide “Clinical hematology”], 2006. Pp. 170-196.
- Dameshek W. Some speculations on the myeloproliferative syndromes. Blood, 1951, vol. 6, pp. 372-375.
- James C., Ugo V., Le Couedic J.P. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycytemia vera. Nature, 2005, vol. 434, pp. 1144-1188.
- Baxter E.J., Scott L.M., Campbell P.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, vol. 365, pp. 1054-1061.
- Kralovics R., Passamonti F., Buser A.S. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 2005, vol. 352, pp. 1779-1790.
- Levine R.L., Wadleigh M., Cools J. et al. Activating mutation in the tyrosine kinase JAK2 in polycytemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, vol. 7, pp. 387-397.
- Linda M. Scott, Wei Tong, Ross L. Levine et al. JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. N Engl J Med, 2005, vol. 357, pp. 459-468.
- Rane S. G., Reddy E. P. Janus kinases: components of multiple signaling pathways. Oncogene, 2000, vol. 19, pp. 5662-5679.
- Kralovics R. The role of somatic and hereditary genetic factors in the pathogenesis of myeloproliferative neoplasms. Education program for the 14 congress of the European Hematology Association, 2009, pp. 188-191.
- Guseva S.A., Goncharov Ya.P. The value of JAK2 V617F mutation in the pathogenesis, diagnosis and prognosis of myeloproliferative disorders. Ukrainskiy zhurnal gematologii i transfuziologii, 2007, no. 2, pp. 5-10 (in Russ.).
- Mascarenhas J., Hoffman R. Risk adapted approach to the treatment of primary myelofibrosis. Education program for the 14 congress of the European Hematology Asso-ciation, 2009, pp. 192-199.